FDAnews
www.fdanews.com/articles/134373-genzyme-8217-s-8220-theoretical-cure-8221-for-ms-draws-scrutiny-sanofi

Genzyme’s “Theoretical Cure” for MS Draws Scrutiny, Sanofi

February 16, 2011
Genzyme Corp.’s experimental drug for multiple sclerosis, the treatment central to negotiations in Sanofi-Aventis SA’s $20.1 billion takeover, will profit investors only if its early promise proves true in later tests.
Bloomberg